A Bayesian hierarchical model for DCE-MRI to evaluate treatment response in a phase II study in advanced squamous cell carcinoma of the head and neck

• Published in: Magma (New York, N.Y.) Vol. 24; no. 2; pp. 85 - 96
• Main Authors: Whitcher, Brandon, Schmid, Volker J., Collins, David J., Orton, Matthew R., Koh, Dow-Mu, de Corcuera, Isabela Diaz, Parera, Marta, del Campo, Josep M., deSouza, Nandita M., Leach, Martin O., Harrington, Kevin, El-Hariry, Iman A.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer-Verlag 01.04.2011
• Subjects: Adult; Aged; Antineoplastic Agents - pharmacokinetics; Antineoplastic Agents - therapeutic use; Bayes Theorem; Biomarkers - metabolism; Biomedical Engineering and Bioengineering; Carcinoma, Squamous Cell - drug therapy; Carcinoma, Squamous Cell - metabolism; Computer Appl. in Life Sciences; Contrast Media - pharmacokinetics; Endpoint Determination; Head and Neck Neoplasms - drug therapy; Head and Neck Neoplasms - metabolism; Health Informatics; Humans; Imaging; Lapatinib; Magnetic Resonance Imaging - methods; Medicine; Medicine & Public Health; Middle Aged; Models, Biological; Protein Kinase Inhibitors - therapeutic use; Protein-Tyrosine Kinases - antagonists & inhibitors; Quinazolines - pharmacokinetics; Quinazolines - therapeutic use; Radiology; Research Article; Solid State Physics; Treatment Outcome; Gadolinium; Oncology; Permeability; Perfusion; Bayesian

Object Pharmacokinetic parameters from dynamic contrast-enhanced MRI (DCE-MRI) were used to assess the perfusion effects due to treatment response using a tyrosine kinase inhibitor. A Bayesian hierarchical model (BHM) is proposed, as an alternative to voxel-wise estimation procedures, to test for a...